Novartis AG
NVSEF
$157.90
$6.484.28%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 54.77B | 54.41B | 54.53B | 54.35B | 53.26B |
| Total Other Revenue | 1.93B | 2.17B | 2.14B | 2.02B | 1.92B |
| Total Revenue | 56.69B | 56.58B | 56.67B | 56.37B | 55.19B |
| Cost of Revenue | 14.19B | 13.84B | 13.63B | 13.40B | 13.10B |
| Gross Profit | 42.50B | 42.74B | 43.05B | 42.98B | 42.09B |
| SG&A Expenses | 13.11B | 13.32B | 13.24B | 13.30B | 13.13B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 429.00M | 636.00M | 859.00M | -221.00M | 487.00M |
| Total Operating Expenses | 38.96B | 39.01B | 38.52B | 36.77B | 36.53B |
| Operating Income | 17.74B | 17.57B | 18.16B | 19.61B | 18.66B |
| Income Before Tax | 15.52B | 15.78B | 16.35B | 16.42B | 15.61B |
| Income Tax Expenses | 2.78B | 2.27B | 2.39B | 2.04B | 1.97B |
| Earnings from Continuing Operations | 12.75K | 13.51K | 13.97K | 14.38K | 13.64K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 10.00M | 20.00M | 17.00M | 10.00M | 16.00M |
| Net Income | 12.76B | 13.53B | 13.98B | 14.39B | 13.65B |
| EBIT | 17.74B | 17.57B | 18.16B | 19.61B | 18.66B |
| EBITDA | 22.27B | 22.07B | 22.62B | 24.07B | 23.03B |
| EPS Basic | 6.67 | 7.03 | 7.21 | 7.36 | 6.91 |
| Normalized Basic EPS | 5.33 | 5.28 | 5.46 | 5.98 | 5.64 |
| EPS Diluted | 6.63 | 6.98 | 7.15 | 7.31 | 6.86 |
| Normalized Diluted EPS | 5.30 | 5.25 | 5.42 | 5.94 | 5.60 |
| Average Basic Shares Outstanding | 7.65B | 7.70B | 7.76B | 7.83B | 7.92B |
| Average Diluted Shares Outstanding | 7.70B | 7.75B | 7.81B | 7.88B | 7.97B |
| Dividend Per Share | 4.67 | 4.67 | 4.67 | 3.86 | 3.86 |
| Payout Ratio | 71.08% | 64.15% | 55.91% | 54.32% | 57.26% |